{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:14:35Z","timestamp":1792001675460,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1038\/npp.2017.282","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T12:00:34Z","timestamp":1511179234000},"page":"891-899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes"],"prefix":"10.1038","volume":"43","author":[{"given":"Karl","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey R","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Nakovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tagrid","family":"Lem\u00e9nager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1086-3067","authenticated-orcid":false,"given":"Katie","family":"Witkiewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"key":"BFnpp2017282_CR1","volume-title":"Inventory of Drinking Situations: User\u2019s Guide","author":"HM Annis","year":"1987","unstructured":"Annis HM, Graham JM, Davis CS (1987) Inventory of Drinking Situations: User\u2019s Guide. Addiction Research Foundation: Toronto, ON, Canada."},{"key":"BFnpp2017282_CR2","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","volume":"295","author":"RF Anton","year":"2006","unstructured":"Anton RF, O\u2019Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003\u20132017.","journal-title":"JAMA"},{"key":"BFnpp2017282_CR3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/npp.2011.182","volume":"37","author":"RF Anton","year":"2012","unstructured":"Anton RF, Litten RZ, Falk DE, Palumbo JM, Bartus RT, Robinson RL et al (2012). The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders. Neuropsychopharmacology 37: 402\u2013411.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2017282_CR4","volume-title":"Manual for the Beck Depression Inventory-II","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Brown GK (1996) Manual for the Beck Depression Inventory-II. Psychological Corporation: San Antonio, TX, USA."},{"key":"BFnpp2017282_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/archpsyc.1993.01820240059008","volume":"50","author":"CR Cloninger","year":"1993","unstructured":"Cloninger CR, Svrakic DM, Przybeck TR (1993). A psychobiological model of temperament and character. Arch Gen Psychiatry 50: 975\u2013990.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2017282_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2307\/2136404","volume":"24","author":"S Cohen","year":"1983","unstructured":"Cohen S, Kamarck T, Mermelstein R (1983). A global measure of perceived stress. J Health Soc Behav 24: 385\u2013396.","journal-title":"J Health Soc Behav"},{"key":"BFnpp2017282_CR7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.biopsych.2012.03.023","volume":"72","author":"LM Fucito","year":"2012","unstructured":"Fucito LM, Park A, Gulliver SB, Mattson ME, Gueorguieva RV, O\u2019Malley SS (2012). Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. Biol Psychiatry 72: 832\u2013838.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017282_CR8","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.addbeh.2012.06.018","volume":"38","author":"A Gl\u00f6ckner-Rist","year":"2013","unstructured":"Gl\u00f6ckner-Rist A, L\u00e9menager T, Mann K,,PREDICT Study Research Group (2013). Reward and relief craving tendencies in patients with alcohol use disorders: results from the PREDICT study. Addict Behav 38: 1532\u20131540.","journal-title":"Addict Behav"},{"key":"BFnpp2017282_CR9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","volume":"86","author":"TF Heatherton","year":"1991","unstructured":"Heatherton TF, Kozlowski LT, Frecker RC, Fagerstr\u00f6m KO (1991). The Fagerstr\u00f6m test for nicotine dependence: a revision of the Fagerstr\u00f6m Tolerance Questionnaire. Addiction 86: 1119\u20131127.","journal-title":"Addiction"},{"key":"BFnpp2017282_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/bs.pbr.2015.07.023","volume":"224","author":"M Heilig","year":"2016","unstructured":"Heilig M, Leggio L (2016). What the alcohol doctor ordered from the neuroscientist. Prog Brain Res 224: 401\u2013418.","journal-title":"Prog Brain Res"},{"key":"BFnpp2017282_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.neubiorev.2009.11.018","volume":"35","author":"M Heilig","year":"2010","unstructured":"Heilig M, Thorsell A, Sommer WH, Hansson AC, Ramchandani VA, George DT et al (2010). Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. Neurosci Biobehav Rev 35: 334\u2013344.","journal-title":"Neurosci Biobehav Rev"},{"key":"BFnpp2017282_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/alcalc\/agg005","volume":"38","author":"A Heinz","year":"2003","unstructured":"Heinz A, L\u00f6ber S, Georgi A, Wrase J, Hermann D, Rey E-R et al (2003). Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake. Alcohol Alcohol 38: 35\u201339.","journal-title":"Alcohol Alcohol"},{"key":"BFnpp2017282_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.biopsych.2011.07.034","volume":"71","author":"D Hermann","year":"2012","unstructured":"Hermann D, Weber-Fahr W, Sartorius A, Hoerst M, Frischknecht U, Tunc-Skarka N et al (2012). Translational magnetic resonance spectroscopy reveals excessive central glutamate levels during alcohol withdrawal in humans and rats. Biol Psychiatry 71: 1015\u20131021.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017282_CR14","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1111\/acer.12893","volume":"39","author":"AT Hillmer","year":"2015","unstructured":"Hillmer AT, Mason GF, Fucito LM, O\u2019Malley SS, Cosgrove KP (2015). How imaging glutamate, \u03b3-aminobutyric acid, and dopamine can inform the clinical treatment of alcohol dependence and withdrawal. Alcohol Clin Exp Res 39: 2268\u20132282.","journal-title":"Alcohol Clin Exp Res"},{"key":"BFnpp2017282_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00213-013-3226-2","volume":"229","author":"A Holmes","year":"2013","unstructured":"Holmes A, Spanagel R, Krystal JH (2013). Glutamatergic targets for new alcohol medications. Psychopharmacology 229: 539\u2013554.","journal-title":"Psychopharmacology"},{"key":"BFnpp2017282_CR16","unstructured":"Institute of Medicine (1990) Broadening the Base of Treatment for Alcohol Problems. National Academies Press: Washington, DC, USA."},{"key":"BFnpp2017282_CR17","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R et al (2014). Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 311: 1889\u20131900.","journal-title":"JAMA"},{"key":"BFnpp2017282_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1146\/annurev-pharmtox-010715-103143","volume":"56","author":"GF Koob","year":"2016","unstructured":"Koob GF, Mason BJ (2016). Existing and future drugs for the treatment of the dark side of addiction. Annu Rev Pharmacol Toxicol 56: 299\u2013322.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BFnpp2017282_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/npp.2009.110","volume":"35","author":"GF Koob","year":"2010","unstructured":"Koob GF, Volkow ND (2010). Neurocircuitry of addiction. Neuropsychopharmacology 35: 217\u2013238.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2017282_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1369-1600.2012.00471.x","volume":"18","author":"HR Kranzler","year":"2013","unstructured":"Kranzler HR, Armeli S, Covault J, Tennen H (2013). Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Addict Biol 18: 193\u2013201.","journal-title":"Addict Biol"},{"key":"BFnpp2017282_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s11920-012-0296-5","volume":"14","author":"HR Kranzler","year":"2012","unstructured":"Kranzler HR, McKay JR (2012). Personalized treatment of alcohol dependence. Curr Psychiatry Rep 14: 486\u2013493.","journal-title":"Curr Psychiatry Rep"},{"key":"BFnpp2017282_CR22","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/acer.12197","volume":"37","author":"RZ Litten","year":"2013","unstructured":"Litten RZ, Castle I-JP, Falk D, Ryan M, Fertig J, Chen CM et al (2013). The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies. Alcohol Clin Exp Res 37: 2128\u20132137.","journal-title":"Alcohol Clin Exp Res"},{"key":"BFnpp2017282_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/acer.12669","volume":"39","author":"RZ Litten","year":"2015","unstructured":"Litten RZ, Ryan ML, Falk DE, Reilly M, Fertig JB, Koob GF (2015). Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin Exp Res 39: 579\u2013584.","journal-title":"Alcohol Clin Exp Res"},{"key":"BFnpp2017282_CR24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/j.1360-0443.1995.tb01088.x","volume":"90","author":"J Littleton","year":"1995","unstructured":"Littleton J (1995). Acamprosate in alcohol dependence: how does it work? Addiction 90: 1179\u20131188.","journal-title":"Addiction"},{"key":"BFnpp2017282_CR25","doi-asserted-by":"publisher","first-page":"516","DOI":"10.15288\/jsad.2009.70.516","volume":"70","author":"M Magill","year":"2009","unstructured":"Magill M, Ray LA (2009). Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs 70: 516\u2013527.","journal-title":"J Stud Alcohol Drugs"},{"key":"BFnpp2017282_CR26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1530-0277.2008.00884.x","volume":"33","author":"K Mann","year":"2009","unstructured":"Mann K, Kiefer F, Smolka M, Gann H, Wellek S, Heinz A et al (2009). Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the Predict Study. Alcohol Clin Exp Res 33: 674\u2013683.","journal-title":"Alcohol Clin Exp Res"},{"key":"BFnpp2017282_CR27","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/adb.12012","volume":"18","author":"K Mann","year":"2013","unstructured":"Mann K, Lem\u00e9nager T, Hoffmann S, Reinhard I, Hermann D, Batra A et al (2013). Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol 18: 937\u2013946.","journal-title":"Addict Biol"},{"key":"BFnpp2017282_CR28","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1111\/acer.12546","volume":"38","author":"K Mann","year":"2014","unstructured":"Mann K, Vollst\u00e4dt-Klein S, Reinhard I, Lem\u00e9nager T, Fauth-B\u00fchler M, Hermann D et al (2014). Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging. Alcohol Clin Exp Res 38: 2754\u20132762.","journal-title":"Alcohol Clin Exp Res"},{"key":"BFnpp2017282_CR29","volume-title":"Form 90: A Structured Assessment Interview for Drinking and Related Behaviors","author":"WR Miller","year":"1996","unstructured":"Miller WR (1996) Form 90: A Structured Assessment Interview for Drinking and Related Behaviors. National Institute on Alcohol Abuse and Alcoholism: Bethesda, MD, USA."},{"key":"BFnpp2017282_CR30","volume-title":"Mplus users guide (Version 7)","author":"LK Muth\u00e9n","year":"2012","unstructured":"Muth\u00e9n LK, Muth\u00e9n BO (2012) Mplus users guide (Version 7). Muth\u00e9n & Muth\u00e9n: Los Angeles, CA, USA."},{"key":"BFnpp2017282_CR31","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/archpsyc.65.4.466","volume":"65","author":"H Myrick","year":"2008","unstructured":"Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K (2008). Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry 65: 466\u2013475.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2017282_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/10705510701575396","volume":"14","author":"KL Nylund","year":"2007","unstructured":"Nylund KL, Asparouhov T, Muth\u00e9n BO (2007). Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Model 14: 535\u2013569.","journal-title":"Struct Equ Model"},{"key":"BFnpp2017282_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/archpsyc.1996.01830030039007","volume":"53","author":"SS O\u2019Malley","year":"1996","unstructured":"O\u2019Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R (1996). Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 53: 217\u2013224.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2017282_CR34","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1001\/jamapsychiatry.2014.3053","volume":"72","author":"DW Oslin","year":"2015","unstructured":"Oslin DW, Leong SH, Lynch KG, Berrettini W, O\u2019Brien CP, Gordon AJ et al (2015). Naltrexone vs Placebo for the Treatment of Alcohol Dependence. JAMA Psychiatry 72: 430.","journal-title":"JAMA Psychiatry"},{"key":"BFnpp2017282_CR35","volume-title":"COMBINE Monograph Series, Volume 2. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence","author":"HM Pettinati","year":"2004","unstructured":"Pettinati HM, Weiss RD, Miller WR, Donovan DM, Ernst D, Rounsaville BJ (2004) COMBINE Monograph Series, Volume 2. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. National Institute on Alcohol Abuse and Alcoholism: Bethesda, MD, USA."},{"key":"BFnpp2017282_CR36","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/adb.12427","volume":"22","author":"CR Roos","year":"2017","unstructured":"Roos CR, Mann K, Witkiewitz K (2017). Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone. Addict Biol 22: 1528\u20131539.","journal-title":"Addict Biol"},{"key":"BFnpp2017282_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1369-1600.2012.00464.x","volume":"18","author":"JP Schacht","year":"2013","unstructured":"Schacht JP, Anton RF, Myrick H (2013). Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol 18: 121\u2013133.","journal-title":"Addict Biol"},{"key":"BFnpp2017282_CR38","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1038\/npp.2017.74","volume":"42","author":"JP Schacht","year":"2017","unstructured":"Schacht JP, Randall PK, Latham PK, Voronin KE, Book SW, Myrick H et al (2017). Predictors of naltrexone response in a randomized trial: reward-related brain activation, OPRM1 genotype, and smoking status. Neuropsychopharmacology 42: 2640\u20132653.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2017282_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/09595230601036960","volume":"26","author":"R Sinha","year":"2007","unstructured":"Sinha R, Li CSR (2007). Imaging stress- and cue-induced drug and alcohol craving: association with relapse and clinical implications. Drug Alcohol Rev 26: 25\u201331.","journal-title":"Drug Alcohol Rev"},{"key":"BFnpp2017282_CR40","volume-title":"Alcohol Dependence Scale (ADS) User\u2019s Guide","author":"HA Skinner","year":"1984","unstructured":"Skinner HA, Horn JL (1984) Alcohol Dependence Scale (ADS) User\u2019s Guide. Addiction Research Foundation: Toronto, ON, Canada."},{"key":"BFnpp2017282_CR41","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/adb.12109","volume":"18","author":"R Spanagel","year":"2013","unstructured":"Spanagel R, Durstewitz D, Hansson A, Heinz A, Kiefer F, K\u00f6hr G et al (2013). A systems medicine research approach for studying alcohol addiction. Addict Biol 18: 883\u2013896.","journal-title":"Addict Biol"},{"key":"BFnpp2017282_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.tips.2007.12.005","volume":"29","author":"R Spanagel","year":"2008","unstructured":"Spanagel R, Kiefer F (2008). Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 29: 109\u2013115.","journal-title":"Trends Pharmacol Sci"},{"key":"BFnpp2017282_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0166-2236(99)01447-2","volume":"22","author":"R Spanagel","year":"1999","unstructured":"Spanagel R, Weiss F (1999). The dopamine hypothesis of reward: past and current status. Trends Neurosci 22: 521\u2013527.","journal-title":"Trends Neurosci"},{"key":"BFnpp2017282_CR44","volume-title":"Manual for the State-Trait Anxiety Inventory","author":"CD Spielberger","year":"1983","unstructured":"Spielberger CD, Gorusch RL, Lushene R, Vagg PR, Jacobs GA (1983) Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press: Palo Alto, CA, USA."},{"key":"BFnpp2017282_CR45","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/archgenpsychiatry.2009.83","volume":"66","author":"J Treutlein","year":"2009","unstructured":"Treutlein J, Cichon S, Ridinger M, Wodarz N, Soyka M, Zill P et al (2009). Genome-wide association study of alcohol dependence. Arch Gen Psychiatry 66: 773.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2017282_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev.med.49.1.173","volume":"49","author":"G Tsai","year":"1998","unstructured":"Tsai G, Coyle JT (1998). The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med 49: 173\u2013184.","journal-title":"Annu Rev Med"},{"key":"BFnpp2017282_CR47","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/alcalc\/agt061","volume":"48","author":"W van den Brink","year":"2013","unstructured":"van den Brink W, Aubin H-J, Bladstr\u00f6m A, Torup L, Gual A, Mann K (2013). Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol 48: 570\u2013578.","journal-title":"Alcohol Alcohol"},{"key":"BFnpp2017282_CR48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/alcalc\/34.2.197","volume":"34","author":"R Verheul","year":"1999","unstructured":"Verheul R, Brink W, van den, Geerlings P (1999). A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol 34: 197\u2013222.","journal-title":"Alcohol Alcohol"},{"key":"BFnpp2017282_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0376-8716(96)01241-0","volume":"41","author":"A Victorio-Estrada","year":"1996","unstructured":"Victorio-Estrada A, Mucha RF, Stephan ER (1996). Excessive drinking situations in German alcoholics: replication of a three-factor model used for North Americans. Drug Alcohol Depend 41: 75\u201379.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp2017282_CR50","unstructured":"World Health Organization (2009) Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. World Health Organization: Geneva, Switzerland."},{"key":"BFnpp2017282_CR51","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/acer.12605","volume":"39","author":"MJ Worley","year":"2015","unstructured":"Worley MJ, Witkiewitz K, Brown SA, Kivlahan DR, Longabaugh R (2015). Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study. Alcohol Clin Exp Res 39: 93\u2013100.","journal-title":"Alcohol Clin Exp Res"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2017282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2017282","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/npp.2017.282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/npp2017282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:59:19Z","timestamp":1684454359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2017282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["BFnpp2017282"],"URL":"https:\/\/doi.org\/10.1038\/npp.2017.282","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,20]]},"assertion":[{"value":"13 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}